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Background
Classical allergen-specific immunotherapy (SIT), using
subcutaneous injections with food extracts, may be
effective but dangerous due to anaphylactic side-effects.
The FAST project (Food Allergy Specific Immunother-
apy) aims at the development of safe and effective treat-
ment of food allergies, targeting persistent and severe
allergy to fish (cod) and fruit (peach). Both are caused
by a single major allergen, parvalbumin (Cyp c 1) and
lipid transfer protein (Pru p 3), respectively. FAST will
apply hypo-allergenic recombinant major allergens for
SIT.
Methods
Two approaches were evaluated for achieving hypo-
allergenicity, i.e. site-directed mutagenesis and chemical
modification. Wildtype (wt) natural and recombinant
allergens and the hypo-allergens were extensively puri-
fied and characterized physico-chemically.. Their stabi-
lity was tested and allergenicity was compared by CAP-
inhibition and histamine release experiments while
immunogenicity was tested in T-cell proliferation
experiments and rabbit and immunizations.
Results
For Cyp c 1, the mutant without calcium-binding site
showed up to a 1000 times reduced allergenicity, while
secondary fold and immunogenicity (human PBMC stimu-
lations/immunization laboratory animals) were retained.
Chemically-modified Cyp c 1 demonstrated poorer capa-
city to stimulate T-cells and immunogenicity in rabbits.
For Pru p 3 allergenicity was reduced to a similar extent
(~1000-fold) for both variants in which disulfide bridges
were disrupted, i.e. either by mutagenesis or by reduction/
alkylation. The disruption resulted in loss of alpha-helical
secondary structure. Assessment of immunogenicity and
stability is still under investigation.
Conclusion
For Cyp c 1, the calcium-binding mutant will now be
produced under GMP regime. For Pru p 3, the final
choice for going into this stage still has to be made.
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